Phathom Pharmaceuticals Inc (PHAT)

May 1, 2026, 8:00 AM EDT - 12 days ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

2026-04-30T12:05:31.000Z - 13 days ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

2026-04-30T12:02:20.000Z - 13 days ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 6:59 AM EDT - 13 days ago

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 20, 2026, 8:00 AM EDT - 23 days ago

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 15, 2026, 1:30 PM EDT - 27 days ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-03-27T09:00:23.000Z - 6 weeks ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2026-03-23T18:25:38.000Z - 7 weeks ago

Phathom Pharmaceuticals management to meet with Cantor

Mar 11, 2026, 3:30 PM EDT - 2 months ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 10:30 AM EST - 2 months ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:39:13.000Z - 2 months ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

2026-02-26T23:40:20.000Z - 2 months ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Feb 26, 2026, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-02-26T12:06:11.000Z - 2 months ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

2026-02-26T12:05:14.000Z - 2 months ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

Feb 26, 2026, 7:00 AM EST - 2 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 17, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 12, 2026, 11:30 AM EST - 3 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

2026-01-08T11:31:01.000Z - 4 months ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

Jan 7, 2026, 10:33 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-01-07T21:10:45.000Z - 4 months ago

Phathom Pharmaceuticals announces common stock offering, no amount given

2026-01-07T21:05:43.000Z - 4 months ago

Phathom Pharmaceuticals files automatic mixed securities shelf

2026-01-07T21:05:23.000Z - 4 months ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

Jan 7, 2026, 4:05 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 4 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

2025-12-11T21:16:52.000Z - 5 months ago

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

2025-12-08T21:30:59.000Z - 5 months ago

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

Dec 2, 2025, 3:25 PM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 9:30 AM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:40 PM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:00 PM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-04T13:16:14.000Z - 6 months ago

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

Nov 4, 2025, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

2025-10-31T13:31:53.000Z - 6 months ago

Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sep 8, 2025, 1:00 PM EDT - 8 months ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:10 AM EDT - 8 months ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 9 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 23, 2025, 4:15 PM EDT - 11 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 11 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 11, 2025, 10:40 AM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 12:27 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 11:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: AGM 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 7, 2024, 1:30 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 6, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Nov 29, 2023, 4:15 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: 6th Annual ISI HealthCONx Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Nov 9, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates